Screener
Neuropace, Inc. NPCE Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 79.6%+2.6pp | 79.6%+4.8pp | 78.5%+4.5pp | 78.1%+4.2pp | 77.1%+2.9pp | |
| Operating margin | -15.3%+9.9pp | -19%+3.9pp | -18.4%+8.7pp | -21.6%+8.6pp | -25.1%+9.4pp | |
| Net margin | -19.3%+11.3pp | -22.6%+6.8pp | -22.4%+11.6pp | -26.4%+10.3pp | -30.7%+10.9pp | |
| Returns | ||||||
| Return on equity | -122.1%+54.9pp | -111.4%+17.1pp | -158.7%+30.6pp | -169.3%+45.3pp | -176.9%+15.2pp | |
| Return on invested capital | -22%+8.6pp | -26%+0.7pp | -26.1%+4.3pp | -28.7%+2.9pp | -30.6%+1.4pp | |
| Efficiency | ||||||
| Asset turnover | 1×+0.1× | 0.9×+0.1× | 1×+0.2× | 0.9×+0.1× | 0.8×+0.1× | |
| Liquidity | ||||||
| Current ratio | 4.9×-0.5× | 5.4×-1.2× | 5.3×-0.1× | 4.9×-0.7× | 5.5×-0.9× | |
| Leverage | ||||||
| Debt-to-equity | 5.9×+2.2× | 4.9×+1.9× | 3.7×-5.4× | 3.8×-3.6× | 3.7×-3.8× | |
| Per Share | ||||||
| Book value per share | $0.35-41.1% | $0.43-44.4% | $0.58+111% | $0.56+67.5% | $0.59+72.7% | |
| Valuation | ||||||
| Market capitalization | $505.61M+73.4% | $442.72M+10.6% | $514.27M+54.0% | $341.07M+69.6% | $352.91M+65.0% | |
| Price / sales | 5.1×+1.7× | 4.6×-0.1× | 5.4×+1.2× | 3.8×+1.1× | 4.2×+1.2× | |
| Price / book | 42.5×+27.5× | 30.6×+14.1× | 27×-14.7× | 18.4×-2.1× | 18.2×-3.5× |
FAQ
- What are Neuropace, Inc.'s profit margins?
- Neuropace, Inc. (NPCE) runs a 79.6% gross margin and a -15.3% operating margin, with a -19.3% net margin.
- Where do Neuropace, Inc.'s ratios come from?
- Every ratio is computed from Neuropace, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
